ReviewAmerican journal of clinical dermatology2018
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Review in American journal of clinical dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- A state-of-the-art systematic review of cancer in hidradenitis suppurativa.Annals of medicine · 2024Pooled it
- Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies.Frontiers in oncology · 2021Pooled it
- Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.JAMA dermatology · 2020Pooled it
- Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis.JAMA network open · 2019Pooled it
- Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials.American journal of clinical dermatology · 2026Trial
- Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.Rheumatology (Oxford, England) · 2023Trial
- Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.American journal of clinical dermatology · 2025Review
- Rare occurrence of penoscrotal basal cell carcinoma: Clinicopathologic findings from a single institution cohort and comprehensive literature review.Virchows Archiv : an international journal of pathology · 2025Article
- A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System.The Journal of investigative dermatology · 2025Article
- Transcriptome dissection reveals the molecular basis of systemic associations in psoriasis.Archives of dermatological research · 2025Article
- Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study.Scientific reports · 2025Observational
- Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.Dermatology and therapy · 2025Article
- Skin cancer prevention in the Polish population during the COVID-19 pandemic.Frontiers in public health · 2025Article
- The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies.Cancers · 2024Review
- The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review.Advances in therapy · 2024Review
- Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab.JAAD international · 2024Article
- Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study.Journal of clinical medicine · 2024Article
- Psoralen: a narrative review of current and future therapeutic uses.Journal of cancer research and clinical oncology · 2024Review
- Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.